CAMBRIDGE, Mass., Sept. 3, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas P. Mathers, Chief Executive Officer, will provide a corporate overview at two investor conferences in September.
| Rodman & Renshaw 17th Annual Global Investment Conference | |
| Date: | Thursday, September 10 |
| Time: | 11:15am Eastern Time |
| Location: | St. Regis Hotel, Library Room (2nd Floor) |
| New York City | |
| Ladenburg Thalmann 2015 Healthcare Conference | |
| Date: | Tuesday, September 29 |
| Time: | 9:30am Eastern Time |
| Location: | Sofitel New York Hotel, Odeon room |
| New York City | |
| Webcast: | The presentation will be webcast live on CoLucid’s Investor Relations website at http://www.colucid.com/investor_relations |
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings.
CONTACT: Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (781) 365-2596 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
Help employers find you! Check out all the jobs and post your resume.
